Approval of three new treatments
Dr. David A. Schwartz says that this an exciting time for physicians who take care of Crohn's patients. Recently, three new biologic treatments have been approved, including certolizumab pegol, natalizumab, and adalimumab. Crohn's disease is often a very difficult disease to treat, hence the importance of having multiple therapeutic and treatment options when patients fail to respond to common courses of therapy, such as infliximab. The development of these new agents may open the door for newer methods of therapy including early interventions and a top-down approach.
Two separate studies were conducted in 2008 to investigate the safety of using infliximab for treating patients with Crohn's disease.